BIOTECH TARGET N V - 14 Nov 2024 Form 4 Insider Report for Molecular Templates, Inc.

Reporting relationship: 10%+ Owner
Issuer ticker: N/A
Reported as of: 14 Nov 2024
Net transaction value: -$433,334
SEC form: 4
Accepted by SEC: 18 Nov 2024, 21:12:24 UTC
Prior SEC filing: 04 Apr 2024
Source filing: View source filing
Reporting owner signature: By: /s/Ivo Betschart

Key filing fact

BIOTECH TARGET N V filed Form 4 for Molecular Templates, Inc. on 18 Nov 2024.

Key facts

This page summarizes BIOTECH TARGET N V's Form 4 filing for Molecular Templates, Inc..
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 18 Nov 2024, 21:12.

Change

Previous filing in this sequence was filed on 04 Apr 2024.
Current net transaction value: -$433,334.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MTEM transaction

Common Stock

Sale

Transaction value: $845,833
Shares: -1,279,820
Change %: -100%
Price: $0.6609
Shares after: 0
Date: 14 Nov 2024
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MTEM transaction Derivative

Prefunded Warrants (right to buy)

Purchase

Transaction value: $316,333
Shares: +134,667
Change %
Price: $2.35
Shares after: 134,667
Date: 02 Apr 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 134,667
Exercise price: $0.001000
Footnotes: F1

MTEM transaction Derivative

Common Warrants (right to buy)

Purchase

Transaction value: $96,167
Shares: +769,334
Change %
Price: $0.1250
Shares after: 769,334
Date: 02 Apr 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 769,334
Exercise price: $2.35
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

BIOTECH TARGET N V is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise.

SEC remarks

Biotech Target N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the indirect beneficial owner of the securities of Molecular Templates, Inc. held directly or indirectly by Biotech Target N.V. This Form 4 is filed jointly by BB Biotech AG and Biotech Target N.V.